Paper Details

  1. Home
  2. Paper Details

Quizartinib inhibits necroptosis by targeting receptor-interacting serine/threonine protein kinase 1.

Author: FuShufang, GuTanrong, HeXiaoyan, HuXinqian, LiMin, MouYan, WangJia, WeiJun, XiaoXin, YeZhi, YouXiaoling, YuYajie, ZhaYunhong, ZhuGuofeng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study identified quizartinib, an FDA-approved drug, as an effective inhibitor of necroptosis, a form of cell death contributing to systemic inflammatory response syndrome (SIRS). Quizartinib directly inhibits RIPK1 kinase activity and protects mice against TNFα-induced SIRS, suggesting its potential for repurposing as a treatment for RIPK1-dependent inflammatory diseases.
Paper Details　
Original Abstract of the Article :
Systemic inflammatory response syndrome (SIRS), at least in part driven by necroptosis, is characterized by life-threatening multiple organ failure. Blocking the progression of SIRS and consequent multiple organ dysfunction is challenging. Receptor-interacting serine/threonine protein kinase 1 (RIPK...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1096/fj.202300600RR

データ提供：米国国立医学図書館（NLM）

Quizartinib: A New Oasis in the Desert of Systemic Inflammatory Response Syndrome

Systemic inflammatory response syndrome (SIRS) is a life-threatening condition characterized by widespread inflammation and organ dysfunction. This study explores a novel approach to treating SIRS by targeting a key mediator of inflammation, receptor-interacting serine/threonine protein kinase 1 (RIPK1). The authors investigated the therapeutic potential of quizartinib, an FDA-approved drug, as a repurposed treatment for SIRS, leveraging a drug repurposing approach.

A Promising Path: Targeting RIPK1 for SIRS Treatment

The study found that quizartinib effectively inhibited necroptosis, a type of cell death that contributes to SIRS, by directly targeting RIPK1. In preclinical models, quizartinib demonstrated promising results, providing protection against TNFα-induced SIRS in mice. The research suggests that quizartinib, a safe and effective drug already approved for other uses, could be a viable treatment option for SIRS.

A New Hope for SIRS Treatment

This research offers a glimmer of hope for individuals suffering from SIRS. The repurposing of quizartinib for SIRS treatment offers a potential new pathway for combating this life-threatening condition. Further clinical trials are needed to confirm the safety and efficacy of quizartinib for this indication.

Dr.Camel's Conclusion

This research reminds us that even in the face of a seemingly insurmountable challenge like SIRS, there may be a hidden oasis of hope. The repurposing of quizartinib offers a new avenue for treating this complex condition, highlighting the importance of innovative approaches to addressing unmet medical needs.

Date :
  1. Date Completed 2023-09-18
  2. Date Revised 2023-09-28
Further Info :

Pubmed ID

37698367

DOI: Digital Object Identifier

10.1096/fj.202300600RR

Related Literature

Article Analysis
・Effects of quizartinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.